Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Phase 2 Clinical Trial of Nab-Paclitaxel + MEDI4736 (Durvalumab) + Neoantigen Vaccine vs. Nab-Paclitaxel + MEDI4736 (Durvalumab) in Patients With Metastatic Triple Negative Breast Cancer

Trial Profile

Randomized Phase 2 Clinical Trial of Nab-Paclitaxel + MEDI4736 (Durvalumab) + Neoantigen Vaccine vs. Nab-Paclitaxel + MEDI4736 (Durvalumab) in Patients With Metastatic Triple Negative Breast Cancer

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Oct 2018

At a glance

  • Drugs Carboplatin (Primary) ; Durvalumab (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary) ; Peptide vaccines (Primary) ; Poly ICLC (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Oct 2018 Planned initiation date changed from 1 Oct 2018 to 15 Dec 2018.
    • 07 Sep 2018 Planned initiation date changed from 25 Aug 2018 to 1 Oct 2018.
    • 07 Aug 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top